PT3505535T - Anticorpo monoclonal anti-pd1, sua composição farmacêutica e seu uso - Google Patents

Anticorpo monoclonal anti-pd1, sua composição farmacêutica e seu uso

Info

Publication number
PT3505535T
PT3505535T PT178428959T PT17842895T PT3505535T PT 3505535 T PT3505535 T PT 3505535T PT 178428959 T PT178428959 T PT 178428959T PT 17842895 T PT17842895 T PT 17842895T PT 3505535 T PT3505535 T PT 3505535T
Authority
PT
Portugal
Prior art keywords
pharmaceutical composition
monoclonal antibody
monoclonal
antibody
pharmaceutical
Prior art date
Application number
PT178428959T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Cttq Akeso Shanghai Biomed Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cttq Akeso Shanghai Biomed Tech Co Ltd filed Critical Cttq Akeso Shanghai Biomed Tech Co Ltd
Publication of PT3505535T publication Critical patent/PT3505535T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7019—Ischaemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT178428959T 2016-08-23 2017-08-22 Anticorpo monoclonal anti-pd1, sua composição farmacêutica e seu uso PT3505535T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610705763.5A CN106977602B (zh) 2016-08-23 2016-08-23 一种抗pd1单克隆抗体、其药物组合物及其用途

Publications (1)

Publication Number Publication Date
PT3505535T true PT3505535T (pt) 2025-01-13

Family

ID=59340342

Family Applications (1)

Application Number Title Priority Date Filing Date
PT178428959T PT3505535T (pt) 2016-08-23 2017-08-22 Anticorpo monoclonal anti-pd1, sua composição farmacêutica e seu uso

Country Status (22)

Country Link
US (2) US12076398B2 (https=)
EP (2) EP4509186A3 (https=)
JP (1) JP7082620B2 (https=)
KR (1) KR102469286B1 (https=)
CN (1) CN106977602B (https=)
AU (2) AU2017316255C1 (https=)
BR (1) BR112019003775A2 (https=)
EA (1) EA201990570A1 (https=)
ES (1) ES3001154T3 (https=)
FI (1) FI3505535T3 (https=)
HU (1) HUE069593T2 (https=)
IL (1) IL264956B2 (https=)
LT (1) LT3505535T (https=)
MX (1) MX2019002268A (https=)
NZ (1) NZ751902A (https=)
PL (1) PL3505535T3 (https=)
PT (1) PT3505535T (https=)
RS (1) RS66372B1 (https=)
SG (1) SG11201901584UA (https=)
SI (1) SI3505535T1 (https=)
WO (1) WO2018036472A1 (https=)
ZA (1) ZA201901781B (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN106977602B (zh) * 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
SG11202000198QA (en) 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
CN109425736B (zh) * 2017-08-25 2021-04-09 北京百普赛斯生物科技股份有限公司 一种检测pd-1抗体血药浓度的方法及试剂盒
MX2020003204A (es) * 2017-09-20 2020-07-20 Regeneron Pharma Metodos de inmunoterapia para pacientes cuyos tumores portan una carga mutacional alta de un gen pasajero.
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
EP3773916A4 (en) * 2018-04-04 2021-12-15 TrueBinding, Inc. PROCEDURES AND COMPOSITIONS FOR BLOCKING THE INTERACTION BETWEEN NON-GLYCOSYLATED PD-1 POLYPEPTIDES
WO2019217455A1 (en) 2018-05-07 2019-11-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
WO2019217457A1 (en) 2018-05-07 2019-11-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
EP3842070A4 (en) * 2018-07-18 2022-04-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. DRUG COMBINATION OF QUINOLINE DERIVATIVE AND ANTIBODY
CN109053889B (zh) * 2018-07-25 2019-06-21 博奥信生物技术（南京）有限公司 一种抗人pd1单克隆抗体及用途
CN109053895B (zh) * 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
EP3946377B1 (en) 2019-04-03 2025-12-10 Orega Biotech Combination therapies based on pd1 and il-17b inhibitors
CN110373415B (zh) * 2019-06-12 2023-06-09 安徽省昂普拓迈生物科技有限责任公司 特异性结合pd-l1蛋白的核酸适配体及其用途
WO2021006199A1 (ja) 2019-07-05 2021-01-14 小野薬品工業株式会社 Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
WO2021023117A1 (zh) * 2019-08-02 2021-02-11 康方药业有限公司 抗ctla4-抗pd-1双特异性抗体及其用途
AU2020324185A1 (en) 2019-08-02 2022-03-03 CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. Anti-PD-1 antibody and medical use thereof
EP4011918A4 (en) 2019-08-08 2023-08-23 ONO Pharmaceutical Co., Ltd. DUAL SPECIFIC PROTEIN
CN110903391B (zh) * 2019-10-25 2021-05-28 东大生物技术(苏州)有限公司 一组pd-l1单克隆抗体及其医药用途
CN112915202B (zh) * 2019-12-06 2025-08-01 正大天晴药业集团股份有限公司 喹啉衍生物与pd-1单抗的药物组合
US20230044381A1 (en) * 2019-12-20 2023-02-09 Guangdong Feipeng Pharmaceutical Co., Ltd Anti-human programmed death-1 monoclonal antibody
CN113117072A (zh) * 2020-01-14 2021-07-16 正大天晴药业集团股份有限公司 喹啉衍生物与pd-1单抗的药物组合
WO2021170750A1 (en) 2020-02-28 2021-09-02 Orega Biotech Combination therapies based on ctla4 and il-17b inhibitors
KR20230004726A (ko) * 2020-04-22 2023-01-06 아케소 바이오파마, 인크. 항-cd73/항-pd-1 이중특이항체 및 이의 용도
US20230235057A1 (en) 2020-04-29 2023-07-27 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bifunctional protein against pd-1 and tgf-beta
CN113754767A (zh) * 2020-06-03 2021-12-07 上海恒润达生生物科技股份有限公司 抗人pd-1抗体及其用途
WO2022068891A1 (zh) * 2020-09-30 2022-04-07 苏州沙砾生物科技有限公司 Pd-1抗体及其制备方法与应用
WO2022108931A2 (en) 2020-11-17 2022-05-27 Seagen Inc. Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
CN113336848B (zh) * 2021-02-03 2022-08-19 上海莱馥医疗科技有限公司 一种抗pd-1抗体及其用途
EP4190819A4 (en) * 2021-03-12 2024-08-14 Akeso Biopharma, Inc. PHARMACEUTICAL COMBINATION CONTAINING BISPECIFIC ANTI-PD-1-ANTI-VEGFA ANTIBODY, AND USE THEREOF
JP2024525758A (ja) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
CA3233205A1 (en) 2021-09-29 2023-04-06 Yu Xia Anti-lag3 antibody, pharmaceutical composition and use
US20250002600A1 (en) 2021-10-06 2025-01-02 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination therapy
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
CN113912710B (zh) * 2021-11-17 2023-05-26 杭州旭科生物技术有限公司 抗新型冠状病毒n蛋白的单克隆抗体及其应用
CN114316053B (zh) * 2021-12-20 2023-09-29 南京诺唯赞检测技术有限公司 一种vce的单克隆抗体及其制备方法
EP4257609A1 (en) 2022-04-08 2023-10-11 iOmx Therapeutics AG Combination therapies based on pd-1 inhibitors and sik3 inhibitors
WO2023198060A1 (zh) * 2022-04-12 2023-10-19 正大天晴药业集团股份有限公司 蛋白酶体抑制剂与抗pd-1抗体的药物组合
US11932693B2 (en) 2022-05-12 2024-03-19 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
TW202413412A (zh) 2022-05-12 2024-04-01 丹麥商珍美寶股份有限公司 在組合療法中能夠結合到ｃｄ２７之結合劑
US20250282873A1 (en) 2022-05-13 2025-09-11 Nanjing Shunxin Pharmaceuticals Co., Ltd. Of Chiatai Tianqing Pharmaceutical Group Drug combination of anti-tim-3 antibody and anti-pd-1 antibody
CN119789867A (zh) * 2022-09-06 2025-04-08 正大天晴药业集团股份有限公司 结合tim-3的抗体与结合pd-1的抗体的药物组合
EP4598960A1 (en) * 2022-10-05 2025-08-13 Chulalongkorn University Monoclonal antibodies against human programmed cell death protein 1 (pd-1)
CN117986356B (zh) * 2022-10-27 2025-07-22 纽迈生物科技(苏州)有限公司 一种制备抗体的方法
JP2025541738A (ja) 2022-12-01 2025-12-23 ビオンテック・ソシエタス・エウロパエア 抗ｐｄ１ａｂと化学療法での併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性抗体
CN121620391A (zh) 2023-04-06 2026-03-06 金麦安博股份有限公司 用于治疗癌症的针对pd-l1和cd137的多特异性结合剂
CN121285385A (zh) 2023-05-12 2026-01-06 金麦安博股份有限公司 能够与ox40结合的抗体、其变体及其用途
WO2025056011A1 (zh) * 2023-09-13 2025-03-20 正大天晴药业集团股份有限公司 包含抗pd-1抗体和第二抗体的药物组合物
WO2025056014A1 (zh) * 2023-09-13 2025-03-20 正大天晴药业集团股份有限公司 包含抗pd-1抗体和第二抗体的药物组合物
TW202540189A (zh) 2023-11-30 2025-10-16 德商生物新技術公司 在組合療法中能夠結合ｏｘ４０之抗體
CN118652343B (zh) * 2024-07-08 2025-05-09 吉林省医菲尼迪生物医药有限公司 一种临床血液免疫细胞以及在治疗疾病中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
CN1753912B (zh) * 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
KR101814408B1 (ko) * 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
CN106432474A (zh) 2010-03-12 2017-02-22 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
ES2676205T3 (es) * 2011-03-31 2018-07-17 Merck Sharp & Dohme Corp. Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
JP6403166B2 (ja) * 2012-08-03 2018-10-10 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 単一抗原抗ｐｄ−ｌ１およびｐｄ−ｌ２二重結合抗体およびその使用方法
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104250302B (zh) * 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
MX375378B (es) 2013-09-27 2025-03-06 Genentech Inc Formulaciones de anticuerpos anti-pdl1.
MY184154A (en) * 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
MX373856B (es) 2014-01-03 2020-03-25 Hoffmann La Roche Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CN104974253A (zh) 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 抗ctla-4/pd-1双特异性抗体、其制备方法及应用
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
CN104987421A (zh) 2015-05-13 2015-10-21 北京比洋生物技术有限公司 抗ctla-4和pd-1的双重可变结构域免疫球蛋白
CN105175545B (zh) * 2015-10-20 2019-01-25 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd-1双功能抗体及其应用
CN105175544B (zh) 2015-10-20 2021-04-09 安徽瀚海博兴生物技术有限公司 一种抗pd-1人源化单克隆抗体及其应用
US10954301B2 (en) 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
CN105754990A (zh) 2016-01-29 2016-07-13 深圳精准医疗科技有限公司 一种pd-1/ctla-4双特异性抗体的制备方法及其应用
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途

Also Published As

Publication number Publication date
RS66372B1 (sr) 2025-02-28
EA201990570A1 (ru) 2019-08-30
AU2017316255A1 (en) 2019-04-11
EP3505535A1 (en) 2019-07-03
WO2018036472A1 (zh) 2018-03-01
CA3034849A1 (en) 2018-03-01
KR102469286B1 (ko) 2022-11-22
US12076398B2 (en) 2024-09-03
IL264956B2 (en) 2023-04-01
HUE069593T2 (hu) 2025-03-28
PL3505535T3 (pl) 2025-03-24
NZ751902A (en) 2022-05-27
AU2024202527A1 (en) 2024-05-16
JP7082620B2 (ja) 2022-06-08
CN106977602B (zh) 2018-09-25
SG11201901584UA (en) 2019-03-28
US20250041409A1 (en) 2025-02-06
AU2024202527B2 (en) 2026-01-15
ZA201901781B (en) 2023-10-25
MX2019002268A (es) 2019-10-21
CN106977602A (zh) 2017-07-25
FI3505535T3 (fi) 2025-01-09
KR20190050994A (ko) 2019-05-14
EP4509186A3 (en) 2025-06-04
BR112019003775A2 (pt) 2019-06-25
EP3505535B1 (en) 2024-10-16
IL264956A (en) 2022-12-01
JP2019534034A (ja) 2019-11-28
ES3001154T3 (es) 2025-03-04
EP3505535A4 (en) 2020-04-15
EP4509186A2 (en) 2025-02-19
AU2017316255B2 (en) 2024-02-01
SI3505535T1 (sl) 2025-04-30
AU2017316255C1 (en) 2024-08-22
US20190321466A1 (en) 2019-10-24
LT3505535T (lt) 2025-01-27

Similar Documents

Publication Publication Date Title
PT3505535T (pt) Anticorpo monoclonal anti-pd1, sua composição farmacêutica e seu uso
IL279015A (en) Anti-interleukin-17A antibody, its pharmaceutical preparation and its use
ZA202101894B (en) Anti-pd-1 and anti-vegfa bifunctional antibody, pharmaceutical composition thereof and use thereof
ZA202206885B (en) Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof
ZA202000113B (en) Anti-ctla-4 antibodies and uses thereof
ZA201806576B (en) Antibodies, pharmaceutical compositions and methods
IL268206A (en) Antibodies directed against bcma and their use
PT3476399T (pt) Anticorpo lag-3, fragmento de ligação a antigénio deste e aplicação farmacêutica deste
ZA201700528B (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
SG11202003782XA (en) Triple-chain antibody, method for preparation and use thereof
ZA202104518B (en) Cd3 antibody and pharmaceutical use thereof
IL271222A (en) Dosing regimens for anti-tim-3 antibodies and their uses
EP3309177A4 (en) Pdl-1 antibody, pharmaceutical composition thereof, and uses thereof
EP3597735A4 (en) CTLA4 ANTIBODIES, PHARMACEUTICAL COMPOSITION AND USES THEREOF
SI3561057T1 (sl) Antitelo proti cd3 in molekula, ki vsebuje navedeno antitelo
SMT202500438T1 (it) Anticorpi anti-pacap umanizzati e loro utilizzi
SMT202200432T1 (it) Anticorpi, frammenti anticorpali anti-ror2, loro immunoconiugati e loro usi
IL274502A (en) Anti-OX40 antibodies and uses thereof
SG11202101435XA (en) ANTIBODY AGAINST IL-1ß, PHARMACEUTICAL COMPOSITION AND USE THEREOF
ZA201807132B (en) Humanized anti-basigin antibodies and the use thereof
EP3404042A4 (en) Monoclonal antibody fnab8 and application thereof
SG11202003585VA (en) Anti-vista antibody and use thereof
ZA201906248B (en) Anti-ceacam1 antibody and use thereof
IL266721A (en) Anti-gp73 antibodies and immunoconjugates
EP3647323A4 (en) ANTI-GITR ANTIBODIES, ANTIGEN BINDING FRAGMENT AND ASSOCIATED PHARMACEUTICAL USE